Drug-induced gastrointestinal (GI) adverse events are a major challenge in developing new therapeutics, particularly for oncology drugs targeting rapidly dividing cells. Current models often fail to accurately predict these toxic effects and lack translational value, emphasizing the need for more advanced 3D tissue models of the intestine.
To fill this gap, MIMETAS developed the OrganoReady® Colon Organoid—a comprehensive and translatable 3D intestine model that combines the benefits of adult stem cell-derived organoids with the OrganoPlate® Organ-on-a-Chip platform. This model allows researchers to predict both on-target and off-target drug effects more effectively. This application note demonstrates how the OrganoReady Colon Organoid can be integrated into toxicology workflows to identify GI toxicity mechanisms using robust multiplex assays, including transepithelial electrical resistance (TEER), cell viability, cytotoxicity, and CYP3A4 activity.
Benefits
• Screenable ready-to-use 3D human colon organoid model
• A translatable adult stem cell-derived solution (license included)
• Validated for drug screening of gastrointestinal adverse effects
• Apical and basolateral access enables the study of orally and intravenously administered drugs
In collaboration with 
Download the app note here
